SLN (Silence Therapeutics) Other Current Receivables : $16.80 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Other Current Receivables?

Silence Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2025 was $16.80 Mil.

Silence Therapeutics's quarterly Other Current Receivables increased from Sep. 2024 ($21.77 Mil) to Dec. 2024 ($25.94 Mil) but then stayed the same from Dec. 2024 ($25.94 Mil) to Mar. 2025 ($16.80 Mil).

Silence Therapeutics's annual Other Current Receivables increased from Dec. 2022 ($19.88 Mil) to Dec. 2023 ($23.69 Mil) and increased from Dec. 2023 ($23.69 Mil) to Dec. 2024 ($25.94 Mil).

Silence Therapeutics Other Current Receivables Historical Data

The historical data trend for Silence Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Other Current Receivables Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Receivables

Get a 7-Day Free Trial

5.74

11.01

19.88

23.69

25.94

Silence Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Current Receivables	Get a 7-Day Free Trial															13.50	16.26	21.77	25.94	16.80

Silence Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Silence Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.